J Bruix

Summary

Affiliation: Universitat de Barcelona
Country: Spain

Publications

  1. doi request reprint New drugs for the treatment of hepatocellular carcinoma
    Eveline Boucher
    BCLC Group, Liver Unit, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Spain
    Liver Int 29:148-58. 2009
  2. pmc Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis
    Sharon L Lederer
    Department of Microbiology, University of Washington, Seattle, WA, USA
    Virol J 3:98. 2006
  3. ncbi request reprint Management of hepatocellular carcinoma
    Jordi Bruix
    BCLC Group Liver Unit Hospital Clínic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Hepatology 42:1208-36. 2005
  4. ncbi request reprint New aspects of diagnosis and therapy of hepatocellular carcinoma
    J Bruix
    BCLC Group, Liver Unit, IDIBAPS, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Oncogene 25:3848-56. 2006
  5. ncbi request reprint Chemoembolization for hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Gastroenterology 127:S179-88. 2004
  6. ncbi request reprint Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma
    J M Llovet
    Liver Unit, , , University of Barcelona, Catalonia, Spain
    Hepatology 33:1124-9. 2001
  7. ncbi request reprint Uptake of technetium-99m DISIDA by bone metastasis from a hepatoma
    F Pons
    Nuclear Medicine Service, Hospital Clinic, Barcelona, Spain
    Clin Nucl Med 13:280-2. 1988
  8. ncbi request reprint Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?
    R Vilana
    Diagnosis Imaging Center, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Eur Radiol 16:2454-62. 2006
  9. ncbi request reprint [Early diagnosis of liver cancer]
    M Sala
    Unidad de Hepatologia, IMD, Hospital Clinic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
    Gastroenterol Hepatol 28:292-7. 2005
  10. doi request reprint Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008

Detail Information

Publications73

  1. doi request reprint New drugs for the treatment of hepatocellular carcinoma
    Eveline Boucher
    BCLC Group, Liver Unit, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Spain
    Liver Int 29:148-58. 2009
    ..In the next years, efforts should be directed to identifying genomic and proteomic profiling that will help us to assess the prognosis and to define what treatment benefits whom, ultimately giving way to personalized medicine...
  2. pmc Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis
    Sharon L Lederer
    Department of Microbiology, University of Washington, Seattle, WA, USA
    Virol J 3:98. 2006
    ..Global transcriptional profiling using oligonucleotide microarrays was therefore performed on liver biopsies from patients with cirrhosis caused by either chronic alcohol consumption or chronic hepatitis C virus (HCV)...
  3. ncbi request reprint Management of hepatocellular carcinoma
    Jordi Bruix
    BCLC Group Liver Unit Hospital Clínic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Hepatology 42:1208-36. 2005
  4. ncbi request reprint New aspects of diagnosis and therapy of hepatocellular carcinoma
    J Bruix
    BCLC Group, Liver Unit, IDIBAPS, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Oncogene 25:3848-56. 2006
    ..Ongoing research should further advance the time at diagnosis and identify new and effective options targeting molecular pathways governing tumor progression...
  5. ncbi request reprint Chemoembolization for hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Gastroenterology 127:S179-88. 2004
    ..The analysis of efficacy in these trials should be adjusted for prognostic factors, such as the presence of symptoms, Child-Pugh class, and segmental vascular invasion...
  6. ncbi request reprint Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma
    J M Llovet
    Liver Unit, , , University of Barcelona, Catalonia, Spain
    Hepatology 33:1124-9. 2001
    ..Iatrogenic dissemination was related to subcapsular location or an invasive tumoral pattern, and has to be considered when selecting curative treatments for HCC or adjuvant therapies before liver transplantation...
  7. ncbi request reprint Uptake of technetium-99m DISIDA by bone metastasis from a hepatoma
    F Pons
    Nuclear Medicine Service, Hospital Clinic, Barcelona, Spain
    Clin Nucl Med 13:280-2. 1988
    ..The use of imaging with biliary tracers can increase the diagnostic specificity when bone metastases from hepatoma are suspected...
  8. ncbi request reprint Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?
    R Vilana
    Diagnosis Imaging Center, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Eur Radiol 16:2454-62. 2006
    ..The 1-month CEUS has a high diagnostic accuracy compared with spiral-CT in the usual assessment of percutaneous treatment response...
  9. ncbi request reprint [Early diagnosis of liver cancer]
    M Sala
    Unidad de Hepatologia, IMD, Hospital Clinic, Universitat de Barcelona, IDIBAPS, Barcelona, Spain
    Gastroenterol Hepatol 28:292-7. 2005
    ..Using this approach, 40-80% of tumors identified are solitary at diagnosis, although only half of these patients can benefit from curative treatment...
  10. doi request reprint Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  11. ncbi request reprint Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma
    M Varela
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit IMD, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Aliment Pharmacol Ther 17:98-102. 2003
    ..To achieve both aims, within the Barcelona Clinic Liver Cancer Group we have developed a staging system that combines prognosis prediction with decision making, thus becoming a useful tool both for practice and research...
  12. ncbi request reprint Prognosis of hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Institut de Malalties Digestives, Hospital Clínic Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Catalonia, Spain
    Hepatogastroenterology 49:7-11. 2002
    ..In addition to predicting prognosis, the staging system should also guide the selection of treatment and this is the major advantage of the classification applied in the Barcelona-Clinic Liver Cancer Group...
  13. doi request reprint Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
    ..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC...
  14. doi request reprint Current strategy for staging and treatment: the BCLC update and future prospects
    Alejandro Forner
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, ICMDM, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Semin Liver Dis 30:61-74. 2010
    ..Finally, patients at end-stage should merely receive palliative care...
  15. ncbi request reprint Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a spanish matched cohort multicenter study
    G Sapisochin
    Department of HBP Surgery and Transplantation, Hospital Universitario Vall d Hebron, Universidad Autonoma de Barcelona, Barcelona, Spain Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, ICMDM, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain Liver Transplantation Unit, Hospital Universitario de Cruces, Universidad del Pais Vasco, Bilbao, Spain Department of HBP Surgery and Transplantation, Hospital Universitario La Fe, Valencia, Spain Liver Transplant Unit, Hospital Universitario de Bellvitge, L Hospitalet, Spain Liver Transplantation Unit, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain Liver Transplant and Hepatology Unit, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain Liver Transplant and Hepatology Unit, Department of Surgery, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain Liver Unit, Department of Gastroenterology, Hospital Universitario Central de Asturias, Oviedo, Spain Hepatology and Liver Transplantation Unit, Hospital Universitario de A Coruña, A Coruna
    Ann Surg 259:944-52. 2014
    ..To evaluate the outcome of patients with hepatocellular-cholangiocarcinoma (HCC-CC) or intrahepatic cholangiocarcinoma (I-CC) on pathological examination after liver transplantation for HCC...
  16. ncbi request reprint High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis
    M Gimenez-Barcons
    Liver Unit, Institut de Malalties Digestives, Departament de Medicina, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    Hepatology 34:158-67. 2001
    ..Therefore, a mutated HCV-PKR-bd phenotype is very common in cirrhotic patients with hepatocellular carcinoma...
  17. ncbi request reprint A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma
    J M Llovet
    BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Eur J Cancer 37:1352-8. 2001
    ..In conclusion, oral eniluracil/5-FU had minimal, if any, activity in patients with inoperable HCC, but the safety profile was acceptable...
  18. ncbi request reprint Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular carcinoma: relationship between detectability and tumor differentiation
    X Calvet
    Liver Unit, Hospital Clinic i Provincial, Barcelona, Spain
    J Nucl Med 29:1916-20. 1988
    ..Since its sensitivity is related to the degree of tumor differentiation, it may be indicated when aspiration cytology is unable to distinguish between well differentiated HCC and reactive changes due to hepatic cirrhosis...
  19. ncbi request reprint Pseudotumoral hepatic tuberculosis
    M Varela
    Liver Unit, Institut de Malaties Digestives, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 39:654. 2003
  20. ncbi request reprint The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Liver Transpl 10:S115-20. 2004
    ..Finally, patients with end-stage disease should receive only palliative treatment to avoid unnecessary suffering...
  21. ncbi request reprint Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet 359:1734-9. 2002
    ..There is no standard treatment for unresectable hepatocellular carcinoma. Arterial embolisation is widely used, but evidence of survival benefits is lacking...
  22. ncbi request reprint Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institut, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Catalonia, Spain
    Hepatology 37:429-42. 2003
    ..In conclusion, chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment. Treatment with tamoxifen does not modify the survival of patients with advanced disease...
  23. ncbi request reprint Prognostic prediction and treatment strategy in hepatocellular carcinoma
    Jordi Bruix
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic i Provincial, Villaroel 170, 08036 Barcelona, Catalonia, Spain
    Hepatology 35:519-24. 2002
  24. ncbi request reprint Selection of candidates with HCC for transplantation in the MELD era
    Margarita Sala
    Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Liver Transpl 10:S4-9. 2004
    ..3%. 5. Priority policies have to be developed and refined to provide a fair and effective distribution of cadaveric organs...
  25. ncbi request reprint Prognostic assessment and evaluation of the benefits of treatment
    Jordi Bruix
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive, Disease Institute, Barcelona, Catalonia Spain
    J Clin Gastroenterol 35:S138-42. 2002
    ..Finally, those with severe liver function or health status impairment constitute the end-stage category and cannot be expected to survive more than 1 year...
  26. ncbi request reprint Treatment of early hepatocellular carcinoma: Towards personalized therapy
    Silvia Tremosini
    BCLC Group, Liver Unit, CIBERehd, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Dig Liver Dis 42:S242-8. 2010
    ..We briefly reviewed therapeutic management for early HCC, taking into account that any recommendation should be delivered in the clinical setting and based on an individualised evaluation of each patient...
  27. pmc Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation
    J M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Gut 50:123-8. 2002
    ..Survival after liver transplantation for early hepatocellular carcinoma (HCC) is worsened by the increasing dropout rate while waiting for a donor...
  28. ncbi request reprint Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma
    Margarita Sala
    Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Hepatology 40:1352-60. 2004
    ..Accordingly, initial complete tumor necrosis should be considered a relevant therapeutic target irrespective of tumor size and liver function...
  29. ncbi request reprint Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
    Alejandro Forner
    BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clinic, University of Barcelona, Spain
    Hepatology 47:97-104. 2008
    ..These results validate the American Association for the Study of Liver Disease (AASLD) guidelines...
  30. ncbi request reprint Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics
    Maria Varela
    Liver Unit, IMDM, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, CIBER HEPAD, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, IDIBAPS, Barcelona, Spain
    J Hepatol 46:474-81. 2007
    ..This study assesses the safety, pharmacokinetics and efficacy of transarterial chemoembolization using drug eluting beads (DEB), an embolizing device that slowly releases chemotherapy to decrease systemic toxicity...
  31. ncbi request reprint Treatment of hepatocellular carcinoma
    Alejandro Forner
    Liver Unit, Institut de Malalties Digestives i Metaboliques, BCLC Group, IDIPAPS, Hospital Clinic, University of Barcelona, C Villarroel 170, E 08036 Barcelona, Spain
    Crit Rev Oncol Hematol 60:89-98. 2006
    ..Finally, the patients with severe cancer-related symptoms or great tumor burden belong to the terminal stage and only benefit from symptomatic treatment...
  32. doi request reprint Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma
    Jordi Rimola
    BCLC Group Radiology Department, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Institut d Investigacions Biomédiques August Pi y Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 50:791-8. 2009
    ..If washout is not registered, a biopsy should be mandatory for diagnosis...
  33. doi request reprint [Treatment of advanced hepatocellular carcinoma]
    Alejandro Forner
    Unidad de Oncología Hepática BCLC, Servicio de Hepatologia, ICMDM, Hospital Clinic, IDIBAPS, Universidad de Barcelona, Barcelona, Espana
    Gastroenterol Hepatol 33:461-8. 2010
    ..The present article provides a review of the treatment of advanced-stage HCC, with special emphasis on the distinct agents that are currently under evaluation...
  34. ncbi request reprint MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation
    Marta Burrel
    Radiology Department, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Hepatology 38:1034-42. 2003
    ..In conclusion, MRA has a high diagnostic accuracy for HCC > or =10 mm and is more sensitive than triphasic helical CT in nodules sized 10 to 20 mm. MRA is the optimal technique for HCC staging prior to curative therapies...
  35. ncbi request reprint Treatment of hepatocellular carcinoma: is there an optimal strategy?
    Maria Varela
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Villarroel 170, Barcelona, Spain
    Cancer Treat Rev 29:99-104. 2003
    ..Finally, patients with end-stage disease with heavily impaired liver function (Child-Pugh class C) or severe physical impairment (performance status 3-4) die within 6 months and should receive only symptomatic treatment...
  36. ncbi request reprint p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma
    Carolina Armengol
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Hepatol 38:591-7. 2003
    ..3+/-7 years, 30 males, 44 Child-Pugh's A, 30 HCV-positive) with small hepatocellular carcinoma (HCC, size: 3.1+/-1.5cm, 40 solitary at pathological examination)...
  37. ncbi request reprint Prognostic prediction in patients with hepatocellular carcinoma
    Margarita Sala
    Liver Unit, Hospital Clinic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, 08036 Barcelona, Spain
    Semin Liver Dis 25:171-80. 2005
    ..It considers tumor stage, liver functional status, physical status, and cancer-related symptoms and, by dividing patients into early, intermediate, advanced, and end-stage categories, provides a link to treatment indication...
  38. ncbi request reprint Hepatitis B virus and hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 39:S59-63. 2003
  39. doi request reprint Novel advancements in the management of hepatocellular carcinoma in 2008
    Josep M Llovet
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, CIBERehd, Hospital Clinic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Hepatol 48:S20-37. 2008
    ..Now, the research effort faces other areas of unmet need, such as the adjuvant setting of resection/local ablation and combination therapies...
  40. ncbi request reprint Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound
    Ramon Vilana
    Radiology Department, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
    Hepatology 51:2020-9. 2010
    ..However, none of these lesions displayed washout on MRI...
  41. ncbi request reprint Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation
    Ramon Vilana
    Radiology Department, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Calle Villarroel, 170, 08036 Barcelona, Spain
    J Clin Ultrasound 31:119-28. 2003
    ..We compared the usefulness of Levovist-enhanced power Doppler imaging (PDI) and helical CT in the depiction of tumor vascularity before and after percutaneous ablation of small hepatocellular carcinomas (HCCs)...
  42. doi request reprint Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma
    Amelia J Hessheimer
    BCLC Group, Liver Unit, Hospital Clinic, IDIBAPS, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, University of Barcelona, Catalonia, Spain
    Eur J Gastroenterol Hepatol 22:1239-44. 2010
    ..Recent studies have identified cases of hepatocellular carcinoma (HCC) arising in cryptogenic cirrhosis and proposed that many of them may be attributable to nonalcoholic fatty liver disease (NAFLD)...
  43. ncbi request reprint Hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Cli nic i Provincial, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain
    Lancet 362:1907-17. 2003
    ..Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC...
  44. pmc IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
    Victoria Tovar
    HCC Translational Laboratory, BCLC Group, Liver Unit and Pathology Department, Hospital Clinic, CIBERehd, IDIBAPS, C Villarroel 170, Catalonia, Spain
    J Hepatol 52:550-9. 2010
    ..We analyzed the underlying molecular mechanisms of IGF signaling activation in early hepatocellular carcinoma (HCC; BCLC class 0 or A) and assessed novel targeted therapies blocking this pathway...
  45. doi request reprint Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
    Alejandro Forner
    Liver Unit, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, August Pi i Sunyer Institute of Biomedical Investigations, Biomedical Center for Research into Hepatic and Digestive Diseases CIBEREHD, University of Barcelona, Barcelona, Spain
    Cancer 115:616-23. 2009
    ..The current report provides an assessment of the agreement/concordance between both RECIST and the EASL guidelines for the evaluation of response to therapy...
  46. ncbi request reprint Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line
    Carolina Armengol
    BCLC Group, Liver Unit, Digestive Disease Institute, Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Clin Cancer Res 10:2150-7. 2004
    ....
  47. ncbi request reprint Liver transplantation in hepatocellular carcinoma
    Josep Fuster
    Barcelona Clinic Liver Cancer BCLC Group, Department of Surgery, Digestive Disease Institute, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Villaroel 170, 08036 Barcelona, Catalonia, Spain
    Transpl Int 18:278-82. 2005
    ..The development of adult living donor liver transplantation has proved to be a good alternative in this type of patients even if they do not fulfill the conventional criteria...
  48. ncbi request reprint Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study
    Josep Fuster
    Department of Surgery, Hospital Clinic, University of Barcelona, Spain
    Hepatogastroenterology 51:536-40. 2004
    ..The objective of our study is to assess the usefulness of intra-abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients...
  49. ncbi request reprint High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation
    Margarita Sala
    Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain
    Liver Transpl 10:1294-300. 2004
    ..In conclusion, this policy is clinically effective and could further improve the outcome of resected patients...
  50. ncbi request reprint Expected developments in hepatology
    Xavier Forns
    Liver Unit, Hospital Clinic, Institut d Investigaciones Biomèdiques August Pi i Sunyer, University of Barcelona, Spain
    Best Pract Res Clin Gastroenterol 16:957-70. 2002
    ..The risk factors and primary, secondary and tertiary prevention of the condition are also analysed. Finally, the development of new therapeutic strategies for hepatocellular carcinoma is evaluated by evidence-based studies...
  51. doi request reprint Angiogenesis in liver disease
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    J Hepatol 50:604-20. 2009
    ....
  52. ncbi request reprint Focus on hepatocellular carcinoma
    Jordi Bruix
    BCLC Group, Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Cancer Cell 5:215-9. 2004
  53. ncbi request reprint Hepatocellular carcinoma in the setting of liver transplantation
    Maria Varela
    Barcelona Clinic Liver Cancer BCLC Group, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Liver Transpl 12:1028-36. 2006
  54. ncbi request reprint Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma
    Maria W Smith
    Department of Microbiology, School of Medicine, and Washington National Primate Research Center, University of Washington, Seattle, Washington 98195, USA
    Cancer Res 63:859-64. 2003
    ..Thus, high throughput methods coupled with high-order statistical analyses may result in the development of new diagnostic tools for liver malignancies...
  55. ncbi request reprint Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision
    Jordi Bruix
    Liver Transpl 9:700-2. 2003
  56. ncbi request reprint Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Divisions of Liver Disease and Recanati Miller Transplantation Institute, Department of Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA
    Semin Liver Dis 26:248-53. 2006
    ..Only a few small studies with heterogeneous target populations and treatments applied are available. The results of these studies are inconsistent and do not provide compelling evidence to accept down-staging as a standard of care...
  57. pmc Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation
    Sigal Kremer-Tal
    Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    J Hepatol 46:645-54. 2007
    ..Hepatocellular carcinoma (HCC) has the most rapidly rising cancer incidence in the US and Europe. The KLF6 tumor suppressor is frequently inactivated in HCC by loss-of-heterozygosity (LOH) and/or mutation...
  58. pmc Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
    Derek Y Chiang
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 68:6779-88. 2008
    ..Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies...
  59. ncbi request reprint Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma
    Elisa Wurmbach
    Mount Sinai Liver Cancer Program, Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 45:938-47. 2007
    ....
  60. ncbi request reprint A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA
    Gastroenterology 131:1758-67. 2006
    ..Small liver nodules approximately 2 cm are difficult to characterize by radiologic or pathologic examination. Our aim was to identify a molecular signature to diagnose early hepatocellular carcinoma (HCC)...
  61. ncbi request reprint Diagnosis and staging of hepatocellular carcinoma prior to transplantation: expertise or failure
    Maria Varela
    Liver Transpl 12:1445-7. 2006
  62. ncbi request reprint Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients
    Maria Varela
    J Hepatol 44:8-10. 2006
  63. ncbi request reprint HCC surveillance: who is the target population?
    Jordi Bruix
    Hepatology 37:507-9. 2003
  64. ncbi request reprint Treatment strategies for hepatocellular carcinoma in cirrhosis
    W Scott Helton
    Department of Surgery, University of Illinois, Chicago, IL, USA
    J Gastrointest Surg 7:401-11. 2003
  65. ncbi request reprint Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers
    Maria W Smith
    Department of Microbiology, School of Medicine, University of Washington, Seattle, WA 98195, USA
    Hepatology 38:1458-67. 2003
    ..In conclusion, our microarray analysis identified several potential gene markers of HCV-associated liver disease and contributed to our rapidly expanding database of experiments describing HCV pathogenesis...
  66. ncbi request reprint Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization
    Josep M Llovet
    Radiology 230:300-1; author reply 301-2. 2004
  67. ncbi request reprint Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma
    Sigal Kremer-Tal
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 40:1047-52. 2004
    ..In conclusion, we propose that KLF6 is deregulated by loss and/or mutation in HCC, and its inactivation may contribute to pathogenesis in a significant number of these tumors...
  68. ncbi request reprint Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography
    Riccardo Lencioni
    Department of Radiology, University of Pisa, Pisa, Italy
    Dig Dis Sci 50:533-7. 2005
    ..0167). Ferucarbotran-enhanced MR imaging is superior to spiral CT in clinical management of patients with suspected hepatic malignancy...
  69. doi request reprint Liver cancer: An evolving challenge reaching research maturity
    Jordi Bruix
    Hepatology 47:1103-4. 2008
  70. ncbi request reprint Diagnosis of Small HCC
    Jordi Bruix
    Gastroenterology 129:1364. 2005
  71. pmc Molecular targeted therapies in hepatocellular carcinoma
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
    Hepatology 48:1312-27. 2008
    ..Ultimately, a molecular classification of HCC based on genome-wide investigations and identification of patient subclasses according to drug responsiveness will lead to a more personalized medicine...
  72. ncbi request reprint Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care
    Alejandro Forner
    Hepatology 47:5-7. 2008